← Back to Screener
NewcelX Ltd. Ordinary Shares (NCEL)
Price$2.49
Favorite Metrics
Price vs S&P 500 (26W)-90.58%
Price vs S&P 500 (4W)-10.40%
Market Capitalization$11.40M
All Metrics
Book Value / Share (Quarterly)$6.94
Cash Flow / Share (Quarterly)$-11.60
Price vs S&P 500 (YTD)28.94%
EPS (TTM)$-5.27
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-5.27
EPS (Annual)$-12.83
ROI (Annual)-140.85%
Cash / Share (Quarterly)$7.40
ROA (Last FY)-88.70%
EBITD / Share (TTM)$-6.96
Cash Flow / Share (Annual)$-13.52
P/B Ratio3.95x
P/B Ratio (Quarterly)4.18x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-12.20x
ROA (TTM)-65.92%
EPS Incl Extra (Annual)$-12.83
Current Ratio (Annual)2.69x
Quick Ratio (Quarterly)2.50x
3-Month Avg Trading Volume0.08M
52-Week Price Return-82.76%
Revenue / Employee (TTM)$0
52-Week High$30.80
EPS Excl Extra (Annual)$-12.83
26-Week Price Return-86.60%
Quick Ratio (Annual)2.56x
13-Week Price Return0.40%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.77x
Enterprise Value$8.324
Revenue / Employee (Annual)$0
Cash / Share (Annual)$5.27
3-Month Return Std Dev87.10%
Net Income / Employee (TTM)$-2
ROE (Last FY)-140.85%
Net Interest Coverage (Annual)-33.15x
EPS Basic Excl Extra (Annual)$-12.83
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-5.27
ROI (TTM)-100.99%
Revenue / Share (Annual)$0.00
Forward P/E0.01x
Price vs S&P 500 (52W)-112.59%
Year-to-Date Return31.58%
5-Day Price Return19.62%
EPS Normalized (Annual)$-12.83
ROA (5Y Avg)-273.89%
Month-to-Date Return17.92%
EBITD / Share (Annual)$-11.84
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-5.27
P/B Ratio (Annual)4.65x
Book Value / Share (Annual)$4.45
Price vs S&P 500 (13W)-0.29%
Beta0.23x
Revenue / Share (TTM)$0.00
ROE (TTM)-100.99%
52-Week Low$1.83
Analyst Recommendations
Jan 2025
Feb 2025
Mar 2025
Apr 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NCELNewcelX Ltd. Ordinary Shares | — | — | — | — | $2.49 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
NewcelX Ltd develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases using integrated stem-cell and neuroscience platforms. The company targets major unmet medical needs including ALS and Type 1 Diabetes through regenerative treatment approaches. Headquartered in Ness Ziona, Israel, NewcelX seeks to deliver scalable solutions to significant patient populations.